Physician profile
Benjamin D Abramowitz
NPI 1376800078
$3,097.38
in general payments reported to CMS, 2019-2025
23 companies · $921 in 2025
The $921 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.10 · 2020: $87.32 · 2021: $55.57 · 2022: $458 · 2023: $752 · 2024: $803 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,476.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $834.82 | 2022-2025 | Lumigan, Xen Glaucoma Treatment System, Vuity |
| Sight Sciences, INC. | $453.34 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $377.12 | 2022-2025 | Clareon, Hydrus Microstent, Lensx |
| Tarsus Pharmaceuticals, INC. | $357.57 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $143.73 | 2023-2024 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Rxsight INC | $140.97 | 2022-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Bausch & Lomb Americas INC. | $137.73 | 2023-2025 | Miebo, Vyzulta |
| Sun Pharmaceutical Industries INC. | $85.85 | 2024 | |
| Allergan, INC. | $73.78 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $69.76 | 2023 | Acthar |
| Oyster Point Pharma, INC. | $63.74 | 2022-2024 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $57.17 | 2022 | |
| Thea Pharma INC. | $45.44 | 2023-2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $39.91 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $39.50 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $33.46 | 2025 | Idosetr |
| Harrow Eye, LLC | $24.93 | 2024 | Vevye |
| Dompe US, INC. | $22.99 | 2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $22.10 | 2022 | |
| Medtronic, INC. | $21.14 | 2025 | |
| Lensar, INC. | $19.11 | 2024 | Lensar Laser System |
| Pacira Pharmaceuticals Incorporated | $17.87 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Abramowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.